Key Highlights

  • Revenue was USD 341.25 million against a USD 340.76 million estimate, with EPS of USD 0.32 against USD 0.31.
  • Adjusted Earnings per diluted share were USD 0.52, against USD 0.45 in the year-earlier quarter.
  • The selling season added a record 1.3 million covered lives and over 85 new clients, with near 100% retention.
  • Full year 2026 Revenue is guided to USD 1.365 billion to USD 1.385 billion, with the midpoint raised.

What did a record selling season add to a quarter in which revenue reached USD 341.25 million? Progyny (NASDAQ:PGNY) reported 1.3 million new covered lives, its largest in a single season, and more than 85 new clients. Chief executive Pete Anevski said the company again reached near 100% retention for 2027 and described Demand from existing accounts for broader coverage and for newer pregnancy, parenting and menopause services.

What the Selling Season and Client Base Show

The company had 607 fertility and family building clients at September 30, 2026, against 553 a year earlier. Average members were 7,176,000 in the quarter, against 6,757,000. Management said the majority of the new clients and lives are stated to go live in the first quarter of 2027, with a meaningful number launching mid-year, and that some of the newest clients already launched in 2026. The company cited more than 660 clients and approximately 8.3 million covered lives once all new clients are live in 2027.

Utilization across all members was 0.56% against 0.54%, and assisted reproductive treatment cycles were 16,723 against 15,981.

Revenue, Profit and Margins

Revenue was USD 341.3 million, up 8.9% from USD 313.3 million, which the company attributed to more clients and covered lives. Fertility benefit services revenue was USD 223.4 million, up 10.6%, and pharmacy benefit services revenue was USD 117.9 million, up 5.8%.

Gross profit was USD 83.7 million, up 15% from USD 72.8 million, and gross Margin was 24.5% against 23.2%. Management linked the change to efficiencies in delivering care management services and lower stock-based compensation. Net Income was USD 26.3 million, or GAAP EPS of USD 0.32, against USD 13.9 million, or USD 0.15. Adjusted EBITDA was USD 58.4 million, up 6.3%, with an adjusted EBITDA margin of 17.1% against 17.5%, as the company noted planned platform investments.

Cash, Buybacks and Guidance

Operating cash flow was USD 56.6 million against USD 50.7 million. Cash, cash equivalents and marketable securities were USD 195.6 million, a decrease of USD 41.3 million from June 30, with the company stating that share repurchases offset operating cash generation. It has no debt, and its USD 200 million revolving Credit Facility is undrawn.

In the quarter the company repurchased nearly 3 million shares for USD 82.7 million under its May 2026 program, which carries an authorization of up to USD 200 million; approximately USD 51 million remains. Repurchases total nearly 11 million shares in 2026.

For full year 2026, revenue is guided to USD 1.365 billion to USD 1.385 billion, net income to USD 107.0 million to USD 110.6 million, adjusted EBITDA to USD 235.0 million to USD 240.0 million, and adjusted EPS to USD 2.09 to USD 2.13. The fourth quarter revenue range is USD 344.7 million to USD 364.7 million. Management stated that 2027 financial guidance is planned for its year-end results in February.

Numbers in Context

Revenue of USD 341.25 million sits alongside GAAP EPS of USD 0.32, adjusted EPS of USD 0.52 and a client count of 607. Management also named 1.3 million new covered lives and USD 195.6 million of cash and marketable securities.

Looking ahead, management pointed to first quarter 2027 go-lives, approximately 8.3 million covered lives once all new clients are live, and fourth quarter adjusted EPS guidance of USD 0.53 to USD 0.58. It also named February as the month for 2027 guidance.